A greater proportion of participants with type 2 diabetes achieve treatment targets with insulin degludec/liraglutide versus insulin glargine 100 units/mL at 26 weeks: DUAL VIII, a randomized trial designed to resemble clinical practice

This report presents the efficacy and safety of insulin degludec/liraglutide (IDegLira) versus insulin glargine 100 units/mL (IGlar U100) as initial injectable therapy at 26 weeks in the 104‐week DUAL VIII durability trial (NCT02501161). Participants (N = 1012) with type 2 diabetes (T2D) uncontrolle...

Descripción completa

Detalles Bibliográficos
Autores principales: Sesti, Giorgio, Bardtrum, Lars, Dagdelen, Selcuk, Halladin, Natalie, Haluzík, Martin, Őrsy, Petra, Rodríguez, Martin, Aroda, Vanita R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2020
Materias:
Brief Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187233/
https://www.ncbi.nlm.nih.gov/pubmed/31903724
http://dx.doi.org/10.1111/dom.13957

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7187233/
https://www.ncbi.nlm.nih.gov/pubmed/31903724
http://dx.doi.org/10.1111/dom.13957

Ejemplares similares